Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240253 · ClinicalTrials.gov registry record · Phase 4
A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT00240253 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 200 participants.
The verdict
NCT00240253, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes who are not achieving glycemic targets.
Interventions
- DRUG pramlintide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00240253
The ClinicalTrials.gov registry entry for NCT00240253 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pramlintide acetate is the first listed.
NCT00240253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00240253 about?
NCT00240253 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes". The purpose of this study is to evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes who are not achieving glycemic targets.
What is the current status of trial NCT00240253?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2005-10. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00240253?
The interventions under investigation include: pramlintide acetate (DRUG).
Who is sponsoring clinical trial NCT00240253?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.